TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (Nasdaq:CGEN) announced today the successful demonstration of functional activity for splice variants of c-Met receptor, MCP1 chemokine, and ANP hormone. The existence of these potential therapeutic candidates had initially been predicted in silico utilizing a Compugen discovery engine. These drug candidates are of potential use in the treatment of various types of cancer, inflammatory diseases, and cardiovascular indications, respectively.
